

## Pathophysiology and Treatment of Gallbladder Cancer

Guest Editors:

**Dr. Philip De Reuver**

Department of Surgery, Radboud  
University Medical Centre, 6500  
HB Nijmegen, The Netherlands

**Dr. Chella van der Post**

Department of Pathology,  
Radboud University Medical  
Centre, 6500 HB Nijmegen, The  
Netherlands

Deadline for manuscript  
submissions:

**closed (31 January 2022)**

### Message from the Guest Editors


Dear Colleagues,

Gallbladder cancer (GBC) is a rare and highly lethal neoplasm of the biliary tract. GBC demonstrates significant geographic, age-, gender-, and ethnicity-related differences in incidence, but the cause of GBC and its pathophysiology is not well understood. (Epi)Genetics or environmental factors may play an essential role in the development of GBC. Other possible risk factors include cholelithiasis, obesity, gallbladder polyps, chronic infections, and an abnormal pancreaticobiliary duct junction. However, most patients with GBC do not have any of the known risk factors apart from age. It could be hypothesized that different causes of gallbladder cancer also imply different treatment strategies.

This Special Issue will focus on the current insights into the pathophysiology, treatment and predictive factors for survival of gallbladder cancer in different geographic areas. This issue aims to improve our understanding in the development of GBC. We look forward to your contributions.

Dr. Philip De Reuver  
Dr. Chella van der Post  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)